ConforMIS, which sells customized joint replacement implants, filed on Friday with the SEC to raise up to $173 million in an initial public offering. The Bedford, MA-based company, which was founded in 2004 and booked $52 million in sales for
All News
As filed with the SEC on 5/21 Proposal No. 1: A proposal to approve an amendment to the Company’s 2012 Equity Incentive Plan increasing the number of shares authorized for awards under the plan by 1,000,000 to a total of 4,568,181 shares.
By Nancy Melville Washington, DC — The use of intrawound vancomycin powder shows efficacy in the prevention of spinal surgical site infections, with the greatest benefit in high-volume institutions, according to a meta-analysis. “The evidence for the use of vancomycin
Newswise — WASHINGTON (May 21, 2015) — The George Washington University (GW) School of Medicine and Health Sciences (SMHS), GW Hospital, and The GW Medical Faculty Associates are pleased to announce Raj Rao, M.D., as the new chair of the
Trellis was founded to provide cost-effective, professional HR Management services for medical device companies through their development and growth cycles, maximizing early-stage value. We establish a competitive advantage by developing a solid employment brand and promoting organizational health, utilizing one-of-a-kind recruiting and
LOS ANGELES–(BUSINESS WIRE)–The Board of Directors of TheraCell, Inc. today announced the appointment of Dr. Gunnar B.J. Andersson, MD PhD, a world-renowned spine surgeon, as a director of the company and member of its surgeon advisory board, effective immediately. Dr.
Thornton Cleveleys (UK), May 21, 2015 – China’s largest manufacturer of implants and related surgical instruments for traumatology and spine surgery, Weigao Orthopaedic Device, is offering a spinal stabilisation system called “Tulip”, which uses semi-rigid rods made from PEEK-OPTIMA® to
OAKLAND, Calif., May 21, 2015 /PRNewswire/ — OrthoTrophix, Inc., a privately held biopharmaceutical company, announced today that the Company completed subject enrollment and all scheduled dosing in its Phase 2 clinical study of TPX-100 in subjects with bilateral osteoarthritis (OA) of
© 2025 MedDeviceJobs.com Powered by Careerleaf
v.4.6.1